HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists), HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators), TOP1 inhibitors(DNA topoisomerase I inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesRespiratory Diseases

Active Indication

Advanced Malignant Solid NeoplasmEGFR-mutated non-small Cell Lung CancerSolid tumor+ [2]

Inactive Indication-

Originator Organization

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active Organization

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.Shandong Suncadia Medicine Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

RegulationFast Track (United States)

Structure/Sequence

Boost your research with our ADC technology data.

view full example data

Clinical Trials associated with SHR-A2009

CTR20244118

/ RecruitingPhase 3

SHR-A2009对比含铂化疗治疗表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗失败的EGFR突变晚期或转移性非小细胞肺癌的随机对照、开放性、多中心III期研究

[Translation] A randomized, controlled, open-label, multicenter phase III study of SHR-A2009 versus platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations who have failed EGFR tyrosine kinase inhibitor (TKI) therapy

评估 SHR-A2009 对比含铂化疗治疗 EGFR TKI 治疗失败的 EGFR突变晚期或转移性非小细胞肺癌患者的无进展生存期（PFS）（基于盲态独立中心评估）、总生存期（OS）及其它有效性指标，包括PFS（研究者评估）、客观缓解率（ORR）、缓解持续时间（DoR）、疾病控制率（DCR），以及评估患者的安全性。

[Translation]

To evaluate SHR-A2009 in comparison with platinum-based chemotherapy in patients with EGFR-mutated advanced or metastatic NSCLC who have failed EGFR TKI therapy in terms of progression-free survival (PFS) (based on blinded independent central review), overall survival (OS), and other efficacy indicators, including PFS (investigator-assessed), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), and to evaluate the safety of patients.

Start Date29 Nov 2024

Sponsor / Collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NCT06671379

/ RecruitingPhase 3

A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.

Start Date29 Nov 2024

Sponsor / Collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NCT06649331

/ RecruitingPhase 2IIT

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Multicenter, Phase II Trial

This is a prospective, open-label, multicenter, phase II platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.

Start Date21 Oct 2024

Sponsor / Collaborator

Fudan University

100 Clinical Results associated with SHR-A2009

100 Translational Medicine associated with SHR-A2009

100 Patents (Medical) associated with SHR-A2009

100 Deals associated with SHR-A2009

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	29 Nov 2024
EGFR-mutated non-small Cell Lung Cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	29 Nov 2024
Breast Cancer	Phase 2	China	Shandong Suncadia Medicine Co., Ltd.Startup	20 Feb 2024
Solid tumor	Phase 2	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Advanced cancer	IND Approval	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	20 Nov 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05114759 (ESMO2024) Manual	Phase 1	EGFR-mutated non-small Cell Lung Cancer	103	SHR-A2009 9.0 mg/kg	(cdgfvgnoov) = 56.3% of 103 pts, with all occurring in ≥5% being hematotoxicities. ayhktuurdj (xpvgumbwfk ) View more	Positive	14 Sep 2024
				SHR-A2009 9.0 mg/kg (Prior PBC treated)
NCT05114759 (ESMO 12023 \| ESMO 22023) Manual	Phase 1	HR-positive/HER2-low Solid Tumors EGFR mutations	42	SHR-A2009	(mnkixvsqqo) = ycgeotawqy ouqhlnaphh (anurttlbsg ) View more	Positive	23 Oct 2023
				SHR-A2009 (1.5 mg/kg)	(jznhyqrulq) = tkmjovhqig fpxzeebyzg (aqdmgvfhqw ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis